Neuralink Corp., the brain-computer interface (BCI) startup founded by Elon Musk, is projecting over $1 billion in annual revenue by 2031, with plans to implant its brain chips in 20,000 people each year. These ambitious projections were revealed in internal documents reviewed by Bloomberg, highlighting Neuralink’s aggressive growth targets and expansion roadmap.
Neuralink Revenue and Implant Goals: What to Expect by 2031
According to the confidential investor presentation, Neuralink expects to:
- Launch three core neural implant products
- Operate five dedicated clinics by 2030
- Conduct 10,000 surgeries annually by 2030
- Reach 20,000 surgeries per year by 2031
- Achieve over $1 billion in annual revenue
The Telepathy chip, Neuralink’s flagship product, enables brain-to-device communication, allowing users to control digital devices using only their thoughts.
Neuralink’s Brain Chip Products
By 2030, Neuralink plans to release at least three commercial brain chip implants:
1. Telepathy
- Function: Brain-to-device interface
- Status: First commercial launch expected by 2029
- Use case: Enables paralysed users to control smartphones, computers, and devices mentally
2. Blindsight
- Function: Vision restoration
- Projected Launch: 2030
- Use case: Aims to help blind individuals regain sight
3. Deep
- Function: Treat neurological disorders
- Use case: Targets conditions like Parkinson’s disease and tremors
The revenue estimates are based on an assumed $50,000 reimbursement rate per surgery. With a projected 10,000 surgeries annually by 2030, Neuralink could generate over $500 million in yearly revenue from Blindsight alone.
Neuralink’s Current Progress and Clinical Trials
Although the company is in the early human testing phase, with fewer than 10 known recipients, Neuralink has already demonstrated mind-controlled video editing, internet browsing, and video game playing by paralysed patients. The company is also experimenting with vision restoration in monkeys.
Milestones to Date:
- Founded: 2017
- First human implant: January 2024
- FDA trials ongoing
- Funding raised: $1.3 billion
- Valuation: $9 billion (PitchBook, 2025)
In April 2025, Neuralink launched a global search for human volunteers to participate in trials of its Telepathy chip.
Regulatory Challenges Still Ahead
Despite its promising technology, Neuralink faces significant regulatory scrutiny. The U.S. Food and Drug Administration (FDA) has not yet approved any BCIs for permanent human use. Like other companies in the neurotech space, Neuralink must prove the long-term safety, stability, and benefit of its implants.
Elon Musk has acknowledged the challenge but remains optimistic. He is known for ambitious tech timelines, such as Tesla’s Robotaxi, which debuted in test mode years after initial promises.
The Brain-Tech Race: Neuralink vs. Competitors
Neuralink is one of several companies racing to commercialise brain-machine interfaces, a field gaining momentum among tech giants, biotech firms, and medical research institutions. The goal is to help individuals with neurological conditions regain mobility, independence, and communication abilities through mind-controlled technology.
